Axitinib 5 mg twice daily
5 mg · ITT
R/M ACC with progression within 9 months (n = 60 total)
Comparator: observation
median progression-free survival: 10.8 months, primary analysis
6-month progression-free survival: 73%, 6 months
progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline
objective response rate: 0%, primary analysis
disease control rate: 100%, primary analysis
Axitinib vs observation (randomized Phase 2) · NCT02859012
Observation
none · ITT
R/M ACC with progression within 9 months
median progression-free survival: 2.8 months, primary analysis
6-month progression-free survival: 23%, 6 months
disease control rate: 51.9%, primary analysis
median overall survival: 27.2 months, axitinib median not reached; P 0.226
Axitinib vs observation (randomized Phase 2) · NCT02859012
Axitinib + avelumab
axitinib 5 mg twice daily + avelumab · Single arm
R/M ACC (n = 28 evaluable)
confirmed objective response rate: 18%, primary analysis
median progression-free survival: 7.3 months, primary analysis
median overall survival: 16.6 months, primary analysis
Axitinib + avelumab Phase 2 (MD Anderson)
Axitinib + avelumab, ACC-I subtype
as above · Single arm
ACC-I (exploratory biomarker analysis of 28 patients)
median progression-free survival: 1.8 months, updated analysis; exploratory
Axitinib + avelumab Phase 2 (MD Anderson)
Axitinib + avelumab, ACC-II subtype
as above · Single arm
ACC-II (exploratory)
median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I
Axitinib + avelumab Phase 2 (MD Anderson)